Crohn's disease (CD) can involve any part of the gastrointestinal tract. We aimed to characterize clinical, endoscopic, histologic features and treatment outcomes of CD patients with oesophageal involvement.
Introduction
Crohn's disease (CD) is a lifelong disease arising from an interaction between genetic and environmental factors. It can involve any part of the gastrointestinal tract, but the most common locations are the terminal ileum and colon. Oesophageal involvement is not usual. Nevertheless, more than 100 cases of oesophageal CD have been published since the first report of Franklin and Taylor in 1950 [1] [2] [3] . Prevalence of 0.3-10% is suggested in adults but population-based studies are lacking [3] [4] [5] [6] [7] .
More frequent oesophageal involvement has been implicated in studies reporting on pediatric CD patients (4.2-42%) 8, 9 . Wide variations are generally attributed to whether asymptomatic patients with histological involvement are included in the analysis. Gastroduodenoscopy is not considered a prerequisite for CD mapping in most guidelines and especially in asymptomatic adults 9, 10 . Oesophageal CD can present as an erosive-ulcerative esophagitis, oesophageal stricture, or fistula, thus sharing many features of other more common diseases of the oesophagus (reflux oesophagitis, infection, drug-induced, related to malignancy or autoimmune diseases). The histologic features of oesophageal CD may be nonspecific further adding on diagnostic challenge. The optimal treatment of oesophageal CD is unknown because controlled trials are lacking. Most physicians use proton pump inhibitors (PPI) as an add-on regimen to conventional therapy and have a lower threshold for starting anti-TNF therapy compared to disease located elsewhere, given the expected poor prognosis 10 .
We aimed to describe diagnostic work-up, interventions and outcome of a series of patients with CD located in the oesophagus.
Materials and Methods

Study design
The European Crohn's and Colitis Organisation (ECCO) CONFER [COllaborative Network For
Exceptionally Rare case reports] projects are based on an initiative introduced by ECCO to support individual investigators in identifying, assembling and reporting together rare Inflammatory Bowel Disease (IBD) cases of clinical relevance, which are otherwise seldom reported. The core of CONFER methodology is selecting certain topics worthy of investigation out of case proposals submitted by physicians involved with IBD. The Steering Committee makes an initial selection, identifying those cases with the highest scientific interest and proximity to the purpose of CONFER project. A Feasibility Network, comprised of 30-35 high volume IBD centers around the globe, is asked to identify similar cases and the final decision is again taken by the Steering Committee based on the outcome of networking. This topic then becomes a CONFER project. ECCO supports dissemination of a call to identify similar cases encountered by IBD physicians worldwide using several tools; announcements in the ECCO annual congress and in national and international IBD meetings across Europe, e-mailing to all ECCO members, posting in ECCO website and ECCO eNews, flyers and personal communication between ECCO members. Physicians are then prompted to report their case(s) using a pre-determined standardized case report form. The call for the present case series was entitled "Oesophageal Crohn's Disease". No financial support or input in the collection of data, the analysis or the publication of the data collected is provided by ECCO. ECCO and/or any of its staff members may not be held liable for any information published in good faith in the ECCO CONFER articles.
Patients and procedures
All CD patients with oesophageal involvement diagnosed either throughout the course of CD or at diagnosis were eligible for inclusion in this study. Diagnosis of oesophageal CD was based on clinical presentation, endoscopic appearance and histological findings 10 
Results
Patients' background information
A total of 15 centers responded to our call and 50 cases were initially reported. Ten patients were excluded due to lack of compatible histologic data and thus 40 cases were included in the analysis.
Patients' characteristics are shown in Table 1 . Mean (±SD, range) age at CD diagnosis was 23 years (±12.6, 3-71). Only 2 patients (5%) were current smokers. A family history of IBD was reported in 7.5% of patients. CD was exclusively located in the upper GI tract in 4 patients and solely in the oesophagus in 2 while in the rest, ileal disease was present in 9 (22.5%), colonic in 3 (7.5%) and ileocolonic in 24 (60%) patients. Gastric involvement was generally seen in 15 patients (37.5%). Of those, only two had active Helicobacter pylori infection. Thirteen patients (32.5%) had received at least one anti-tumor necrosis factor (TNF) agent and six (15%) had undergone a CD-related surgery (partial small bowel resection, stricturoplasty, partial colectomy, ileo-cecal resection or rectal abscess drainage) prior to oesophageal involvement diagnosis.
Oesophageal CD diagnosis
Oesophageal disease characteristics are summarized in Table 2 The most common symptom was dysphagia or odynophagia in 19 patients (47.5%). Thirteen patients (32.5%) were asymptomatic at oesophageal disease diagnosis. As mentioned before, esophageal CD was diagnosed during follow-up in 14 patients. Upper GI endoscopy was performed in these patients due to: dysphagia and/or odynophagia in 6, weight loss in 2, heartburn in 1, iron deficiency anemia in 2, reassessment of pre-existing upper GI CD in 2 and in a pediatric patient with active disease.
Distal oesophagus was the most common site of involvement, either alone (n=15, 37.5%) or as part of involvement of the entire oesophagus (n=10, 25%). There were several endoscopic findings, but erosions and small ulcers were more frequently seen (n=31, 77.5%). Interestingly, one patient presented with an oesophageal fistula. Representative pictures of endoscopic findings are shown in On histology, seventeen patients (42.5%) had acute and chronic inflammation while 12 (30%) were found to have chronic inflammation with predominantly lymphocytes and plasma cells. Non-caseating granulomas were less frequently seen (n=8, 20%).
Oesophageal disease treatment and outcomes
Thirty-four patients (85%) had an inflammatory phenotype of oesophageal CD and were treated with a variety of medications (Table 2) . Treatment was decided not only upon esophageal CD activity but also on extraesophageal involvement. Most patients were treated with more than one drug (n=33, 82.4%). Proton-pump inhibitors (PPIs, n=37, 92.5%) were administered in the majority of patients, Discussion This is a retrospective, international study reporting a series of CD patients with oesophageal involvement. Although this study was not designed to assess the prevalence of oesophageal CD, we can infer that onset of this presentation may be under-recognized due to the infrequent performance of upper GI endoscopy in asymptomatic individuals with CD, especially adults.
Diagnostic work up includes a combination of oesophageal-specific symptoms, a history of extraoesophageal CD, and endoscopic and histologic features that are supportive but not specific for CD.
Almost one third of the patients in our series were asymptomatic while the rest complained of nonspecific symptoms like dysphagia/odynophagia, heartburn, vomiting, chest pain and weight loss, resembling gastro-oesophageal reflux disease, similar to previous reports. 3, 5, 7 Most patients had at least one additional test to exclude more common diagnoses (87.5%). CD of the oesophagus is not difficult to diagnose in cases in which other segments of the digestive tract are simultaneously involved or in patients with a prior history of CD, but isolated oesophageal disease requires exclusion of more common diseases, so we suggest that in the absence of a previous diagnosis of CD, an Histological features are also not always compatible with CD. In our cohort, chronic inflammation was the most common presentation; eight patients (20%) had non-caseating granulomas in the setting of chronic inflammation, a higher rate than the one reported in the literature (7-9%), perhaps due to the inclusion of pediatric patients as granuloma formation is more often seen in younger patients, and mainly in the severe, active penetrating disease. 12, 13 CD limited to the oesophagus is rare and has been described in case reports. 6, 11, 14, 15 In our cohort there were only 2 cases. Oesophageal involvement was established at CD diagnosis in two thirds of the patients (65%) and during follow-up in one third (35%). Almost half of the patients demonstrated perianal disease, which is also in line with previous reports. 16 One third of the cohort had extraintestinal manifestations, slightly less than global data for CD, which can also be justified by the inclusion of pediatric patients. 17 There are limited data on the most suitable management of oesophageal CD due its rarity and the frequent coexistence of distal disease which leads to the use of standardized therapeutic protocols.
ECCO guidelines suggest treating mild esophageal CD with PPI only and more severe or refractory disease with systemic corticosteroids or an anti-TNF-based strategy. 10 A c c e p t e d M a n u s c r i p t 
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